A First-in-human Trial of GRT7041 in Healthy Participants
NCT ID: NCT07289776
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
70 participants
INTERVENTIONAL
2026-01-14
2026-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose \[SAD\]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose \[MAD\]), and the Treatment Period will be up to 14 days (for Part 2).
The trial will include a Screening Visit, an in-house stay period and Follow-up (FU) Visit/End-of-Trial (EoT) Visit.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Part 1: SAD with up to five cohorts SAD1 to SAD5 (n = 40). To be conducted in adult males and women of non-childbearing potential (WONCBP).
* Part 2: MAD with up to three cohorts, MAD1 to MAD3 (n = 30) dosed once daily (QD) for a period of 14 days. To be conducted in adult males only.
The trial design also evaluate the potential interaction of GRT7041 with a CYP3A4 index substrate that will be assessed separately in all cohorts in Part 2 (MAD) of the trial.
Dosing in Parts 1 and 2 will be conducted under fasted conditions, except for the SAD3 cohort in Part 1 (SAD), where participants will also receive a standardized breakfast (SAD3b treatment) to assess the effect of food.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 2: MAD
With up to three cohorts, MAD1 to MAD3 (n = 30) dosed once daily (QD) for a period of 14 days. To be conducted in adult males only.
Placebo
Placebo to match GRT7041 dose strength
Midazolam
Solution
GRT7041 MAD
Multiple ascending doses
Part 1: SAD
With up to five cohorts SAD1 to SAD5 (n = 40). To be conducted in adult males and WONCBP
GRT7041 SAD
Single ascending doses
Placebo
Placebo to match GRT7041 dose strength
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GRT7041 SAD
Single ascending doses
Placebo
Placebo to match GRT7041 dose strength
Midazolam
Solution
GRT7041 MAD
Multiple ascending doses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants must sign the ICF before any trial-related assessments.
Exclusion Criteria
2. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk for treatment complications/ participation in the trial unsafe.
3. Any disease or conditions known to interfere with the absorption, distribution, metabolism, or excretion of the IMP.
4. Evidence or medical history of clinically significant and relevant psychiatric issues as assessed by the Investigator.
5. Confirmed or suspected history of clinically relevant drug allergy.
6. Major surgical procedure, within 30 days prior to ICF signing, or anticipation of need for a major surgical procedure during the trial.
7. Blood loss of 500 mL or more (eg, owing to blood donation) within 90 days before Screening Visit.
8. The participant has used any medication, including herbal remedies or over-the-counter medication within 2 weeks (or 5 half-lives, whichever is longer) before the start of the trial intervention or anticipated use during the trial, unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the trial.
9. The participant is enrolled in another clinical trial unless it is an observational (non-interventional) clinical trial or during the follow-up period of an interventional trial) or has received an IMP in another clinical trial within 30 days before Day 1 or within 5 times the elimination half-life of the IMP, whichever is longer.
10. Reluctance to comply with contraception requirements.
11. Evidence or history of alcohol or drug abuse including positive or missing alcohol breath test or drugs of abuse test(s).
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Grünenthal GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Zealand Clinical Research (NZCR)
Christchurch, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cory Sellwood, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP7041-01
Identifier Type: -
Identifier Source: org_study_id